Glenmark receives final approval from USFDA for generic version of Benicar Tablets

26 May 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, the generic version of Benicar Tablets, 5 mg, 20 mg and 40 mg, of Daiichi Sankyo, Inc. Glenmark’s Olmesartan Medoxomil Tablets will be manufactured by Glenmark Pharmaceuticals in its manufacturing facility located in Goa, India.

According to IMS Health sales data for the 12 month period ending March 2017, the Benicar Tablets, 5 mg, 20 mg and 40 mg market achieved annual sales of approximately $950.0 million.

Glenmark’s current portfolio consists of 115 products authorized for distribution in the US marketplace and approximately 69 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 



Glenmark Pharma Share Price

1986.75 -5.95 (-0.30%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×